Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alvotech
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
Alvotech is celebrating an “historic milestone” as it became a publicly listed company in New York, with its shares set to also trade in its domestic Iceland next week.
Alvotech will cease to be a privately listed company next week, with its merger with special purpose acquisition company Oaktree Acquisition Corp. II set to close “on or about 15 June.”
Stada and Alvotech have announced the launch of the Hukyndra higher-strength adalimumab biosimilar rival to Humira in selected European countries, with a wider roll-out to follow in the coming months.
- Generic Drugs
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Alvotech Iceland
- Alvotech Germany GmnH
- Alvotech Swiss AG